Biocept, Inc.

Welcome to BIOCEP's KOL webinar. All participants will be in list-only mode. You may submit online questions at any time today using the window on the webcast. Please note, this event is being recorded. I would now like to turn the conference over to Jody Kane. Please go ahead.

This is Jody Kane with LHA. Thank you all for joining us today. During this webinar, management will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Overlooking statements include all statements that are not historical facts and generally can be identified by terms such as anticipates, estimates, believes, could, expects, intends, may, plans, potential, predicts, projects, should, will, would, or the negative of those terms. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those statements, as well as performance or achievements that are implied by forward-looking statements. In particular, there is significant uncertainty about the duration, severity, and contemplated impact of the COVID-19 pandemic. This means results could change at any time. And the contemplated impact of COVID-19 on BIOSEP's operations, financial results, and outlook is the best estimate based on the information for today's discussion. For details about these risks, please see the company's SEC filings. The content of this webinar contains time-sensitive information that is accurate only as of today, April 8, 2021. Except as required by law, BioCEP disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this event. Now I'd like to turn the webinar over to BioCEP's Director of Clinical and Translational Affairs, Dr. Barbara Blau. Barbara?

Thank you, Jody, for the introduction. My name is Barbara Blau. I'd like to welcome you to the BioCept Neuro-Oncology KOL webinar. I am pleased to introduce today's presenters. Joining me from BioCept are Michael Null, President and CEO, Dr. Michael Dugan, Senior Vice President, Chief Medical Officer, and Medical Director. It is my great pleasure to introduce to you our featured speakers. Joining us are Dr. Amir Azadi, who is a medical oncologist specializing in the neuro-oncology and assistant professor in the Department of Neurology at the Barrow Neurological Institute. Dr. Nicholas Blondin, who is assistant professor of Clinical Neurology at the Yale School of Medicine, and Dr. Priya Kumthaker, who is a UCNS certified neuro-oncologist from Northwestern University. Dr. Kumthaker serves in leadership roles with the National Clinical Trials Network and was named the Alliance for Clinical Trials National Executive Officer of Neuro-Oncology in 2016. Dr. Coomptaker is serving as the principal investigator for BioCEP's 4C registry study. And with that introduction, I would like to turn the webinar over to Michael Nall. Michael?